GlassScriptPhysician profile
Rajeev N Shenoy
NPI 1467485102
$8,077.18
in general payments reported to CMS, 2019-2025
46 companies · $1,642 in 2025
The $1,642 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $619 · 2020: $126 · 2021: $968 · 2022: $2,069 · 2023: $1,413 · 2024: $1,239 · 2025: $1,642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,228 · Education: $65.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,228.07 |
| Education | $65.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,120.14 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $716.29 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $642.85 | 2019-2025 | Farxiga, Lokelma, Flumist Quadrivalent |
| Otsuka America Pharmaceutical, INC. | $604.97 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $568.27 | 2019-2025 | Veltassa |
| Amgen INC. | $545.80 | 2019-2025 | Tavneos, Krystexxa |
| Calliditas Therapeutics US INC. | $411.58 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $409.19 | 2021-2025 | Lupkynis |
| Travere Therapeutics, INC. | $270.01 | 2023-2025 | |
| Fresenius USA Marketing, INC. | $266.96 | 2019-2025 | Velphoro, Velphoro |
| Bard Peripheral Vascular, INC. | $225.42 | 2020-2025 | Covera |
| Bayer Healthcare Pharmaceuticals INC. | $208.94 | 2021-2025 | |
| Glaxosmithkline, LLC. | $207.66 | 2019-2024 | Benlysta, Jesduvroq |
| Mallinckrodt Hospital Products INC. | $203.61 | 2020-2025 | Terlivaz, Acthar |
| Horizon Therapeutics Plc | $201.38 | 2019-2023 | Krystexxa |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $162.52 | 2019-2024 | Rayaldee |
| Cordis US Corp. | $125.00 | 2025 | S.M.A.R.T. Control |
| Daiichi Sankyo INC. | $108.06 | 2019-2025 | Injectafer |
| Alexion Pharmaceuticals, INC. | $106.20 | 2019-2025 | Ultomiris |
| Akebia Therapeutics INC | $88.02 | 2019-2023 | Auryxia |
| Nxstage Medical, INC. | $80.29 | 2024 | |
| Ardelyx, INC. | $74.23 | 2023-2024 | Ibsrela |
| Novo Nordisk INC | $73.04 | 2024-2025 | Ozempic, Rybelsus |
| Vbi Vaccine (Delaware) INC. | $67.00 | 2022-2023 | Prehevbrio |
| Genzyme Corporation | $56.93 | 2019-2023 | |
| Apellis Pharmaceuticals, INC. | $54.65 | 2025 | Empaveli |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $49.09 | 2019-2025 | |
| Scpharmaceuticals INC. | $44.50 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.51 | 2024-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $39.54 | 2022-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $33.38 | 2023-2024 | Jardiance |
| Cvrx, INC. | $32.47 | 2024 | Barostim Neo System |
| Lemaitre Vascular, INC. | $22.04 | 2022 | |
| Genentech USA, INC. | $21.56 | 2025 | Gazyva |
| Alnylam Pharmaceuticals INC. | $21.33 | 2023 | Onpattro |
| Shield Therapeutics INC | $19.02 | 2025 | |
| Janssen Pharmaceuticals, INC | $18.54 | 2019 | |
| Molnlycke Health Care US, LLC | $18.31 | 2025 | Mlnlyckez-Flo Fluidized Positioner, Mepilex Border Sacrum, Mepilex Border Flex |
| Cormedix INC. | $16.83 | 2024 | Defencath |
| Xeris Pharmaceuticals, INC. | $16.74 | 2024 | Keveyis |
| Ascendis Pharma Endocrinology INC | $15.75 | 2025 | Yorvipath |
| Recordati_rare_diseases_inc. | $15.75 | 2021 | |
| Lundbeck LLC | $15.69 | 2019 | |
| Becton, Dickinson and Company | $14.90 | 2024 | Covera |
| Mallinckrodt Enterprises LLC | $12.92 | 2019 | |
| Biomerieux INC | $9.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Shenoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.